Value of adjuvant chemotherapy for patients with pT2N0M0 non ‐small cell lung cancer receiving radical resection

ConclusionACT was valuable for patients with pathological stage IIA (pT2bN0M0) and patients with radiological pure-solid LUAD of pathological stage IB. A combination of radiological features and pathological subtypes could be helpful when selecting patients with pT2N0M0 NSCLCs for ACT.

Source: Thoracic Cancer - December 15, 2023 Category: Cancer & Oncology Authors: Shiqi Chen, Siqian Yang, Yue Zhao, Yang Zhang, Qingyuan Huang, Haoxuan Wu, Hong Hu, Yihua Sun, Yawei Zhang, Jiaqing Xiang, Ting Ye, Haiquan Chen Tags: ORIGINAL ARTICLE Source Type: research